LSM14B

Across TCGA pan-cancer cohorts, LSM14B Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated LSM14B data layer compared with 26 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher LSM14B Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated LSM14B expression acts as an unfavorable survival marker.

STAD, LIHC, and PRAD are the cancer types where LSM14B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	DFS	Median	All	0.287	0.713	.010	12	view →
LIHC	OS	Median	All	0.226	0.773	.008	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
SKCM	OS	Median	All	0.538	0.788	.019	5	view →
COAD	OS	Median	All	0.176	0.673	.011	4	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

LSM14B–STAD (DFS)

Open the STAD breakdown →